Offering Compelling Opportunities for Investment  

Allphild Inc is advancing innovative molecules into transformative treatments to address a range of critical conditions, including:

• Solid tumors;

• Hematological malignancies;

• Traumatic brain injury (TBI);

• Neurodegenerative disorders; 

• Autoimmune diseases; 

• Induction of immune tolerance for transplantation;

• Lung fibrosis.  

The pipeline includes: 

• microRNA (miRNA)-based treatment; 

• Synergistic approach combining CAR-T therapy with the novel molecule that modulates gene expression to prevent CAR-T cell exhaustion; 

• Immunotherapy;

• Cell and gene therapies;

• Cytotoxin conjugates.  

Dr. Xiangfei "Scott" Cheng, the sole inventor of hundreds of innovative molecules, is the Founder and CEO of Allphild  Inc.  U.S. patent applications have been filed for all of these novel molecules.  He brings a unique blend of scientific innovation and executive leadership experience.  Allphild Inc is driven by a mission to deliver transformative change in healthcare.  This leadership reflects a deep commitment to societal impact, coalition-building, and bold, purpose-driven goals.

We are currently seeking seed funding to support the generation of preliminary efficacy and toxicity data.  Several venture capital firms have expressed interest, with funding commitments contingent upon these initial results.

If you are interested in learning more, please contact us.